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EFFICACY AND SAFETY OF SODIUM HYALURONATE IN 
THE TREATMENT OF OSTEOARTHRITIS OF THE 
CARPOMETACARPAL JOINT OF THE THUMB VERSUS 
CORTICOSTEROID 
P Bruehlmann, D Frey, B Salzmann, A Koch, BA Michel 
Department of Rheumatology and Institute of Physical Medicine, 
University Hospital, Zurich, Switzerland 
Aim of Study: To assess whether one intra-articular (i.a.) injec- 
tion of sodium hyaluronate (SH) 1.0% would reduce pain and im- 
prove function over 6 months in patients with rhizarthrosis com- 
pared to corticosteroid. 
Methods:  This pilot, randomised, masked-observer, controlled 
study involved patients with symptomatic osteoarthritis of the car- 
pometacarpal joint of thumb. Pain on rotatory movement was re- 
quired to be >30 mm on 100 mm Visual Analogue Scale (VAS). 
After an analgesic washout period, patients received a single i.a. 
injection of either SH 10 mg/1 ml (Ostenil ® mini, TRB Chemed- 
ica AG, Germany) or triamcinolone acetonide (TA) 10 mg/1 ml. 
Patients were observed over 6 months with visits at Day 7, 
Week 4, 12, 24. Paracetamol was available as rescue analgesia. 
Three dimensions of pain were assessed as efficacy parameters 
and measured on VAS: overall pain of thumb/on rotatory move- 
ment/on joint shifting. Other parameters included VAS pain on 
pinch (tip, key, palmar), physician's assessment of disease activ- 
ity (VAS)and Dreiser Algofunctional Index (0-30). 
Results:  69 patients (mean age 63 years, 53 women) were ran- 
domised; 62 completed the study. Seven failed to complete due to 
adverse events (2), short efficacy duration (2), lack of efficacy (1), 
lost to follow up (1) and consent withdrawal (1). The 69 patients 
(SH=34, TA=35) were analysed as ITT. Mean overall pain values 
in SH group decreased significantly from 42.7 mm at baseline be- 
fore injection to 22.9 mm at Week 24 (p<0.001) and in TA group 
from 45.2 mm to 26.2 mm (p<0.01). No significant intergroup dif- 
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Similar results were found for pain on rotatory movement, pain on 
joint shifting, pain on pinch and disease activity. 
Mean VAS values (mm) 
SH TA 
Baseline Week 24 Basel ine Week 24 
Overall pain 42.7 ±20.5 22.9 ±19.8 45.2 ±19.2 26.2 ±22.3 
Pain on rotatory 
movement 55.4 ±16.7 28.3 ±19.4 55.5 ±15.2 31.6 ±27.8 
Pain on joint shifting 39.7 ±25.7 21.6 ±17.8 37.3 ±20.1 21.6 ±23.3 
Pain on tip pinch 45.1 ±19.3 25.0 ±16.5 39.7 ±21.6 26.0 ±21.4 
Pain on key pinch 37.6 ±24.8 19.9 ±18.3 39.5 ±25.1 24.4 ±22.3 
Pain on palmar pinch 50.5 ±20.4 23.0 ±17.9 45.8 ±23.0 29.1 ±26.0 
Disease activity 55.3 ±14.2 26.3 ±20.3 55.5 ±11.6 22.8 ±18.0 
SH group exhibited a mean baseline Dreiser Index of 10.6 vs 9.5 
in TA group (p=ns). It decreased in both groups to reach 7.8 in 
SH group vs 6.8 in TA group (p=ns). Two patients dropped out of 
the study because of adverse events in SH group (acute low back 
pain and tendopathy of right thumb). 
Conc lus ions :  A single injection of SH led to significant improve- 
ment in pain and function and was as effective as TA for treating 
rhizarthrosis. Sustained improvement was demonstrated in both 
groups at all time points over 6 months. 
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CHONDROITIN SULFATE MAY HAVE DIFFERENTIAL 
EFFECTS ON OA SYMPTOMS RELATED TO DEGREE OF 
RADIOGRAPHIC INVOLVEMENT 
DO Cleqq, DJ Reda, MM Hooper, RW Moskowitz, the GAIT 
Investigators 
School of Medicine, University of Utah, Salt Lake City, UT 
The Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) 
was a randomized double-blind placebo- and celecoxib-controlled 
trial of 1583 OA patients designed to evaluate the efficacy 
of glucosamine (G), chondroitin sulfate (CS), and combination 
(G+CS) in improving osteoarthritis (OA) knee pain. GAIT patients 
had symptomatic and radiographic (Kellgren and Lawrence (KL) 
Grades 2 or 3) OA. We report a subanalysis of GAIT results 
based on interaction of KL Grade and CS response relative to 
placebo. 
As expected, baseline characteristics demonstrated that patients 
with KL3 radiographic disease were significantly older, more 
obese and had more severe OA in terms of disease duration, 
baseline WOMAC, patient global and quality-of-life measures. 
The following table details treatment outcomes by KL Grade. 
Interactions between treatment group and KL Grade are signif- 
Abstract P145 - Table 1 
Outcome Measure KL Chondroitin Sulfate n=318 Placebo n=313 P values 
KL Grade 2 vs 3 CS vs Placebo Treatment group by 
by KL Grade interaction 
Percent treatment responders 
Primary (WOMAC 20) 2 72.6% 63.1% 0.0016 0.1046 0.1668 
3 55.3% 56% 
OME RACT-OARSI 2 71.0% 59.8% 0.0015 0.0721 0.1345 
3 53% 53% 
Change in WOMAC Subscales 
Pain 2 -101.5 -90.3 0.0042 0.0907 0.0753 
3 -59.5 -80.4 
Stiffness 2 -40.7 -37 0.0049 0.0271 0.0120 
3 -18.1 -35.7 
Function 2 -289.6 -218.6 0.0617 0.0100 0.0101 
3 -160.3 -239.2 
Change in Swelling 2 10.6 16.7 0.0508 0.0138 
3 15.0 24.2 
